Journal
MAMMALIAN GENOME
Volume 23, Issue 7-8, Pages 404-415Publisher
SPRINGER
DOI: 10.1007/s00335-012-9398-y
Keywords
-
Categories
Funding
- Marie Curie RTN EUrythron [MRTN-CT-2004-005499]
- European Molecular Biology Organisation [ALT 325-2008]
- Medical Research Council
- National Institute of Health Biomedical Research Centre Programme laboratory
- British Heart Foundation [PG/07/045/22690, RG/10/17/28553] Funding Source: researchfish
- Medical Research Council [G1000801b, MC_UU_12009/3, MC_UU_12009/4, MC_U137761446, MC_UU_12009/1] Funding Source: researchfish
- MRC [MC_UU_12009/4, MC_UU_12009/1, MC_U137761446, MC_UU_12009/3] Funding Source: UKRI
Ask authors/readers for more resources
C16orf35 is a conserved and widely expressed gene lying adjacent to the human alpha-globin cluster in all vertebrate species. In-depth sequence analysis shows that C16orf35 (now called NPRL3) is an orthologue of the yeast gene Npr3 (nitrogen permease regulator 3) and, furthermore, is a paralogue of its protein partner Npr2. The yeast Npr2/3 dimeric protein complex senses amino acid starvation and appropriately adjusts cell metabolism via the TOR pathway. Here we have analysed a mouse model in which expression of Nprl3 has been abolished using homologous recombination. The predominant effect on RNA expression appears to involve genes that regulate protein synthesis and cell cycle, consistent with perturbation of the mTOR pathway. Embryos homozygous for this mutation die towards the end of gestation with a range of cardiovascular defects, including outflow tract abnormalities and ventriculoseptal defects consistent with previous observations, showing that perturbation of the mTOR pathway may affect development of the myocardium. NPRL3 is a candidate gene for harbouring mutations in individuals with developmental abnormalities of the cardiovascular system.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available